Prestige Consumer Healthcare Inc. (PBH) Fair Value 2026

PBH · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.3 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (20/100)

Quick Summary — As of 2026-10-07, Prestige Consumer Healthcare Inc. (PBH) trades at $46.44, versus a $71.49 median fair value across its 12 active models — 53.9% above the current price. QOC: 8.3/10. Value Trap Risk: 20/100 (SAFE). 12/13 models active. Within that set, the Bayesian DCF component alone returns $77.20.

Key Facts

Ticker
PBH
Price
$46.44
Quality Score
8.3/10
Value Trap Risk
20/100
Models Active
12/13
Last Updated
Strength: Bayesian DCF suggests +66.2% upside with 74% confidence
Risk: Limited model coverage (12/13) may reduce confidence

Is Prestige Consumer Healthcare Inc. (PBH) Undervalued or Overvalued in 2026?

According to CirclFi’s 12-model valuation engine, Prestige Consumer Healthcare Inc. (PBH) appears undervalued as of : the median of 12 independent fair value estimates is $71.49, 53.9% above the current price of $46.44. Estimates range from $21.62 to $138.66. PBH scores 8.3/10 on fundamental quality and 20/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. PBH’s +53.9% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -0.0%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Prestige Consumer Healthcare Inc. Stock in 2026? →

What Fair Value Does Each Model Give PBH?

12 Intrinsic Value Models vs. Current Price ($46.44)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $77.20 +66.2%
Intrinsic · High Conviction
 $27.38 -41.0%
Ensemble · Medium Conviction
 $69.76 +50.2%
Scenario · High Conviction
 $73.21 +57.6%
Unlock the Full Matrix

Access 8 additional models including EROIC Spread, Markov DDM, and more.

$2 / day

Billed monthly ($60/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is PBH's Fair Value Range?

Spread across 12 independent models · $21.62 to $138.66

CirclFi's 12 active models place Prestige Consumer Healthcare Inc. (PBH) between $21.62 and $138.66 per share, a spread of 164% of the median. The median of that range — $71.49 — is the fair value CirclFi publishes for PBH, against a current price of $46.44.

Low · Sentiment SOTPHigh · Regime Cross
$21.62median $71.49$138.66
Where the range comes from
Most bearish modelSentiment SOTP$21.62
Most bullish modelRegime Cross-Sectional$138.66
Model agreement8 bullish · 4 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for PBH. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on PBH, not a CirclFi price target. How each model works →

What Is Prestige Consumer Healthcare Inc. (PBH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Prestige Consumer Healthcare Inc.'s intrinsic value is estimated at $71.49, suggesting a +53.9% median upside from the current price of $46.44. While 8 models see room for appreciation, model agreement is not unanimous as 4 models flag potential overvaluation. Model dispersion is worth noting: Regime Cross targets $138.66 (+198.6%), versus Sentiment SOTP at $21.62 (-53.4%). This +252.0% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About PBH?

12 of 13 models are currently active for PBH. Of these, 8 models suggest upside while 4 models suggest overvaluation. Taken together, their median fair value for PBH is $71.49 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $77.20 on its own, implying +66.2% upside from the current price. See which stocks rank higher →

How Does PBH Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, PBH ranks #16 by Quality of Company score. CirclFi's QOC score of 8.3/10 evaluates 32 fundamental signals. A score of 8.3 places PBH in the top tier.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Prestige Consumer Healthcare Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is PBH a Value Trap?

CirclFi's Value Trap algorithm assigns PBH a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Prestige Consumer Healthcare Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Prestige Consumer Healthcare Inc. scores 8.3 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +252.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PBH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PBH's 12 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Prestige Consumer Healthcare Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

SIGASIGA Technologies, Inc.QOC 8.4AMRXAmneal Pharmaceuticals, Inc.QOC 8.3BCRXBioCryst Pharmaceuticals, Inc.QOC 8.4KNSAKiniksa Pharmaceuticals International, plcQOC 8.1ETSTEarth Science Tech, Inc.QOC 8.5ORGOOrganogenesis Holdings Inc.QOC 8.0ALVOAlvotechQOC 6.3YCBDcbdMD, Inc.QOC 5.3GRPSGold River Productions, Inc.QOC 4.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: SIGA · AMRX · BCRX · KNSA · ETST · ORGO · ALVO · YCBD · GRPS · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to PBH?

7 companies across all industries closest to PBH’s Quality of Company score of 8.3/10.

TBBKThe Bancorp, Inc.QOC 8.3MFGMizuho Financial Group, Inc.QOC 8.3SFBSServisFirst Bancshares, Inc.QOC 8.3UDRUDR, Inc.QOC 8.3ASBAssociated Banc-CorpQOC 8.3WTRGEssential Utilities, Inc.QOC 8.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TBBK · MFG · SFBS · UDR · ASB · WTRG · NVDA

Where Does PBH Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

PBH is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Prestige Consumer Healthcare Inc.’s Valuation?

What is Prestige Consumer Healthcare Inc.'s intrinsic value in 2026?

CirclFi puts Prestige Consumer Healthcare Inc. (PBH)'s intrinsic value at $71.49 — the median of 12 independent model estimates as of 2026-10-07, ranging from $21.62 to $138.66. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $77.20 on its own. The Quality of Company score is 8.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PBH overvalued or undervalued right now?

At $46.44, 8 of 12 active models suggest PBH may be undervalued, while 4 indicate potential overvaluation. The median of all 12 fair value estimates is $71.49, 53.9% above the current price of $46.44 — a consensus view that PBH is undervalued. The assessment depends on which methodology best fits Prestige Consumer Healthcare Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 8.3 mean for PBH?

Prestige Consumer Healthcare Inc.'s QOC of 8.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on PBH?

CirclFi analyzes PBH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PBH?

Of the 12 models currently active on PBH, Regime Cross-Sectional is the most bullish at $138.66 per share, and Sentiment SOTP is the most bearish at $21.62. CirclFi's published fair value for PBH is the median of that range, $71.49, not either extreme. The gap between the two ends equals 164% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is PBH a value trap in 2026?

Prestige Consumer Healthcare Inc.'s Value Trap score is 20/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 12-model valuation engine, Prestige Consumer Healthcare Inc. (PBH) has a median fair value of $71.49 — 53.9% above the current price of $46.44 — as of 2026-10-07.” Source: circlfi.com/stock/PBH/ · Methodology
Primary sources for this PBH valuation
  • Financial statements: Prestige Consumer Healthcare Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001295947) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PBH as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on PBH.

Unlock All 12 Fair Values — $60/mo

Cancel anytime · Less than a cup of coffee · Instant access

8 models hidden for PBH Unlock All 12 — $60/mo